Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in early-stage Alzheimer's disease
NCT06022068Phase 2Completed
- Sponsor
- Karolinska Institutet
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in Alzheimer's disease (AD), sponsored by Karolinska Institutet. Primary endpoint: Change in cerebral glucose metabolism at 6 months. Started Sep 2023; status: completed.
02
Drugs
sirolimus
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06022068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022068.